Panaceabio
Live Price
Recent news and updates for PANACEABIO will appear here soon.
"Balanced market signals for PANACEABIO. The stock is currently consolidating with neutral technical indicators and fundamental alignment between current healthcare growth rates and prevailing valuation metrics."
Verified by Stockmo Intelligence Grid
Citing cross-referenced internal documents and market technicals
Panacea Biotec Limited, a biotechnology company, engages in the research, development, manufacture, and marketing of vaccines, pharmaceutical formulations, nutraceuticals, and food and nutrition products in India and internationally. It operates through Vaccines and Pharmaceutical formulations & Nutrition segments. The company's product portfolio includes prescription products in various therapeutic areas, such as oncology, diabetes, gastro-intestinal care, nephrology, orthopedics, pain management, and fever; cold and cough; and betacoronavirus, SARS-CoV-2, typhoid conjugate, pneumococcal conjugate, tetravalent dengue, Mpox, and hepatitis A vaccines, etc. It also offers health supplement products; and paediatric nutrition products under the ChilRunFull, ChilRun 7+, and ChillRun No Sucrose brands. In addition, the company engages in the real estate business. It exports its products to approximately 50 countries. The company has collaboration agreements with the Russian Direct Investment Fund for producing Covid-19 vaccine, and Sputnik-V; and the Indian Council of Medical Research for clinical trials of DengiAll vaccine. Panacea Biotec Limited was incorporated in 1984 and is based in New Delhi, India.
As of the latest market session, Panaceabio (PANACEABIO) is trading at ₹441.2, representing a move of -0.94% from the previous close.
Panaceabio is listed and traded under the ticker symbol PANACEABIO on the National Stock Exchange of India (NSE) and Bombay Stock Exchange (BSE).
Today, Panaceabio's stock price moved by -0.94%. Long-term growth trends depend on company financials, technical moving averages, and sector momentum in the Healthcare industry.
Our proprietary AI Momentum engine calculates a 50% bullish probability for PANACEABIO stock over the next 3-5 days. View the live interactive chart on Stockmo to see dynamic technical forecasting.
Over the past 52 weeks, Panaceabio shares reached a high of ₹647 and hit a low of ₹292.4.
PANACEABIO exhibits standard volatility for a Healthcare stock, with an average daily trading volume of 1,72,520 shares. Detailed technical beta indicators are available on the Stockmo charting engine.
Panaceabio has a market capitalization of ₹2702.38 Cr, designating its size class inside the Healthcare sector.
Panaceabio has a current dividend yield of N/A. Companies may adjust payout ratios depending on quarterly earnings growth and reinvestment opportunities.
Panaceabio's trailing Price-to-Earnings (P/E) ratio is —. This indicates how much investors are willing to pay for every rupee of the company's annual net earnings.
You can purchase Panaceabio (PANACEABIO) shares through any SEBI-registered stockbroker (such as Kite/Zerodha, Groww, or Angel One) by funding your trading account and executing a buy order on the NSE or BSE.
Panaceabio's financial health, solvency, growth, and quality metrics are tracked using our proprietary Multibagger V2 score. You can explore PANACEABIO's detailed 5-tier financial scorecard and compare it with market competitors on the Stockmo Multibagger Screener page.
Institutional order blocks and pristine support/resistance triggers for PANACEABIO are monitored in real-time. View live technical entry levels, stop loss bounds, and target prices on our interactive Supply & Demand Trading Engine or scan entire market segments using the Basket Scanner.
Panaceabio operates inside the Healthcare sector. You can analyze sector-wide trends, relative strengths, and locate top emerging leaders in this space using our Sector Analysis Hub.